[Nephrotic syndrome due to primary renal disease. Study of therapeutic response (author's transl)].
D000284:Administration, Oral; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002699:Chlorambucil / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D007166:Immunosuppressive Agents; D002699:Chlorambucil; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001379:Azathioprine; D011241:Prednisone
Síndrome nefrósico con lesiones glomerulares primarias